News from xencor, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 28, 2015, 08:00 ET

Xencor to Host Second Quarter 2015 Financial Results Webcast and Conference Call on August 4, 2015

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jun 26, 2015, 07:00 ET

Xencor Provides Update on Two Lead XmAb® Product Candidates and Expansion of Bispecific Oncology Pipeline at R&D Day

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jun 12, 2015, 08:00 ET

Xencor to Host R&D Day and Webcast on June 26, 2015

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jun 10, 2015, 08:00 ET

Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 26, 2015, 08:00 ET

Xencor to Present at Jefferies 2015 Healthcare Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

May 13, 2015, 08:00 ET

Xencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory Affairs and Wayne Saville, M.D., as Vice President of Clinical Oncology

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 11, 2015, 08:00 ET

Xencor's XmAb®5871 Program to be Featured in Poster Presentation at European League Against Rheumatism (EULAR) 2015 Annual Meeting

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 04, 2015, 16:01 ET

Xencor Reports First Quarter 2015 Financial and Operating Results

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Apr 29, 2015, 08:00 ET

Xencor to Webcast Presentations at Two Upcoming Conferences in May

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Apr 28, 2015, 08:00 ET

Xencor to Host First Quarter 2015 Financial Results Webcast and Conference Call on May 4, 2015

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Mar 19, 2015, 08:00 ET

Xencor Appoints A. Bruce Montgomery, M.D. to Board of Directors

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Mar 16, 2015, 08:00 ET

Xencor to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Mar 02, 2015, 16:01 ET

Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock

Xencor, Inc. (NASDAQ: XNCR) today announced the completion of an underwritten public offering of 8,625,000 shares of its common stock, including...

Feb 25, 2015, 08:00 ET

Xencor, Inc. Prices Public Offering of Common Stock

Xencor, Inc. (NASDAQ: XNCR) today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock, offered at a...

Feb 23, 2015, 16:04 ET

Xencor, Inc. Announces Proposed Public Offering of Common Stock

 Xencor, Inc. (NASDAQ: XNCR) today announced that it intends to offer and sell, subject to market and other conditions, up to 5,500,000 shares...

Feb 19, 2015, 16:01 ET

Xencor Reports Fourth Quarter and Full Year 2014 Financial Results

 Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Feb 12, 2015, 08:00 ET

Xencor, Inc. to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Feb 05, 2015, 08:00 ET

Xencor to Webcast Presentations at Two Upcoming Conferences in February

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jan 29, 2015, 07:00 ET

Xencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction of Serum IgE in Healthy Volunteers

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jan 29, 2015, 07:00 ET

Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity in Rheumatoid Arthritis

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...